(NASDAQ: KZR) Kezar Life Sciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.33%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34%.
Kezar Life Sciences's earnings in 2026 is -$56,033,000.On average, 5 Wall Street analysts forecast KZR's earnings for 2026 to be -$23,363,318, with the lowest KZR earnings forecast at -$35,614,796, and the highest KZR earnings forecast at -$6,997,053. On average, 5 Wall Street analysts forecast KZR's earnings for 2027 to be -$21,274,964, with the lowest KZR earnings forecast at -$49,774,025, and the highest KZR earnings forecast at -$541,807.
In 2028, KZR is forecast to generate -$24,618,689 in earnings, with the lowest earnings forecast at -$37,998,747 and the highest earnings forecast at -$12,384,165.